Prosecution Insights
Last updated: November 20, 2026

Scribe Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Analysis

Scribe Therapeutics Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 examiners across 5 art units, indicating a broad and distributed prosecution profile. The examiner assignments exceed the art-unit assignments, so some art-unit context is shared even though the matters have separate examination contacts.

SPENCE, JENNIFER SUZANNE is the busiest examiner, with 1 pending matter. No examiner has a larger pending allocation in the supplied data, making application-level coordination important.

Counsel should maintain a central claim and disclosure strategy while adapting responses to the applicable art unit and examiner. The 5-art-unit spread also makes consistent explanations of biotechnology concepts important, particularly where related applications present similar technical issues in different examination settings.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (43%)
3
Medium (43%)
1
Easy (14%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (29%)
§103 only2 (29%)
§112 only1 (14%)
Double-patenting + other1 (14%)
Multi-statute (no §101)1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SPENCE, JENNIFER SUZANNE 1 66.4% +46.6%
JACKSON III, WALTER 1 50.0% +0.0%
CHONG, KIMBERLY 1 72.4% +13.1%
ZARA, JANE J 1 71.1% +16.1%
SU-TOBON, QIWEN NMN 1 75.0% +66.7%
MCLEOD, AFRICA MHAIRIE 1 58.6% +58.1%
RYAN, DOUGLAS CHARLES 1 37.7% +48.8%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18039858 ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS ZARA, JANE J 51d overdue
17641426 COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 RYAN, DOUGLAS CHARLES 31d overdue
18266076 AAV VECTORS FOR GENE EDITING CHONG, KIMBERLY —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18039858 ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS ZARA, JANE J 51d overdue
17641426 COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 RYAN, DOUGLAS CHARLES 31d overdue
18693062 ENGINEERED CASX REPRESSOR SYSTEMS SPENCE, JENNIFER SUZANNE —
18266076 AAV VECTORS FOR GENE EDITING CHONG, KIMBERLY —
18255172 COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A SU-TOBON, QIWEN NMN —
17932798 COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72 MCLEOD, AFRICA MHAIRIE —

Top Art Units

Art UnitApps
1636 2
1635 2
1633 1
1638 1
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18693062 ENGINEERED CASX REPRESSOR SYSTEMS SPENCE, JENNIFER SUZANNE 1633 §103Other Non-Final OA — Pending Mar 18, 2024
18608127 SELF-INACTIVATING VECTORS FOR GENE EDITING JACKSON III, WALTER 1638 §103 Non-Final OA — Pending Mar 18, 2024
18266076 AAV VECTORS FOR GENE EDITING CHONG, KIMBERLY 1636 §103§112 Non-Final OA — Pending Jun 08, 2023
18039858 ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS ZARA, JANE J 1637 §101§102§112 Non-Final OA 51d overdue Pending Jun 01, 2023
18255172 COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A SU-TOBON, QIWEN NMN 1636 §103§112DP Non-Final OA — Pending May 31, 2023
17932798 COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72 MCLEOD, AFRICA MHAIRIE 1635 §112 Final Rejection — Pending Sep 16, 2022
17641426 COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 RYAN, DOUGLAS CHARLES 1635 §101§103§112DP Final Rejection 31d overdue Pending Mar 08, 2022

Managing Scribe Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Scribe Therapeutics Inc. have?

Scribe Therapeutics Inc. has 7 pending office actions as of November 2026, spread across 5 art units and 7 examiners.

Which USPTO examiner handles the most Scribe Therapeutics Inc. applications?

Jennifer Suzanne Spence has the most, with 1 of Scribe Therapeutics Inc.'s pending office actions.

What technology area are Scribe Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month